Lloyd King

567 total citations
24 papers, 370 citations indexed

About

Lloyd King is a scholar working on Molecular Biology, Pharmacology and Oncology. According to data from OpenAlex, Lloyd King has authored 24 papers receiving a total of 370 indexed citations (citations by other indexed papers that have themselves been cited), including 14 papers in Molecular Biology, 6 papers in Pharmacology and 5 papers in Oncology. Recurrent topics in Lloyd King's work include Pharmacogenetics and Drug Metabolism (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Lloyd King is often cited by papers focused on Pharmacogenetics and Drug Metabolism (5 papers), Monoclonal and Polyclonal Antibodies Research (5 papers) and Metabolomics and Mass Spectrometry Studies (3 papers). Lloyd King collaborates with scholars based in United Kingdom, United States and Belgium. Lloyd King's co-authors include David P. Humphreys, Nenad Manevski, Bryan John Smith, Fabien Lecomte, William R. Pitt, Paul E. Stephens, Andrew P. Chapman, David Glover, Shauna West and Bruce Carrington and has published in prestigious journals such as SHILAP Revista de lepidopterología, Journal of Medicinal Chemistry and The American Journal of Gastroenterology.

In The Last Decade

Lloyd King

23 papers receiving 347 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Lloyd King United Kingdom 10 247 92 52 51 45 24 370
Vladas Algirdas Bumelis Lithuania 7 279 1.1× 36 0.4× 28 0.5× 11 0.2× 18 0.4× 11 355
Mary Szatkowski Ozers United States 13 344 1.4× 16 0.2× 53 1.0× 35 0.7× 27 0.6× 16 541
Christopher Chidley United States 8 363 1.5× 69 0.8× 64 1.2× 8 0.2× 13 0.3× 10 538
Alexander S. McColl United States 6 256 1.0× 44 0.5× 47 0.9× 7 0.1× 24 0.5× 8 378
Frédéric Villard Switzerland 10 269 1.1× 30 0.3× 59 1.1× 5 0.1× 27 0.6× 14 504
Bibek Parajuli United States 8 241 1.0× 13 0.1× 115 2.2× 35 0.7× 15 0.3× 18 415
Anna C. Salzberg United States 4 510 2.1× 35 0.4× 40 0.8× 34 0.7× 18 0.4× 5 633
Regina Tugyi Hungary 5 237 1.0× 53 0.6× 94 1.8× 29 0.6× 9 0.2× 6 344
Mark E. Gustafson United States 13 300 1.2× 107 1.2× 17 0.3× 11 0.2× 68 1.5× 28 443
Wanessa Fernanda Altei Brazil 13 292 1.2× 24 0.3× 54 1.0× 14 0.3× 22 0.5× 27 481

Countries citing papers authored by Lloyd King

Since Specialization
Citations

This map shows the geographic impact of Lloyd King's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Lloyd King with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Lloyd King more than expected).

Fields of papers citing papers by Lloyd King

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Lloyd King. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Lloyd King. The network helps show where Lloyd King may publish in the future.

Co-authorship network of co-authors of Lloyd King

This figure shows the co-authorship network connecting the top 25 collaborators of Lloyd King. A scholar is included among the top collaborators of Lloyd King based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Lloyd King. Lloyd King is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Khojasteh, S. Cyrus, Upendra A. Argikar, Lionel Cheruzel, et al.. (2023). Biotransformation research advances – 2022 year in review. Drug Metabolism Reviews. 55(4). 301–342. 4 indexed citations
2.
Khojasteh, S. Cyrus, Upendra A. Argikar, Sungjoon Cho, et al.. (2022). Biotransformation novel advances – 2021 year in review. Drug Metabolism Reviews. 54(3). 207–245. 3 indexed citations
3.
Cox, Benoit, Patrick Barton, Reiner Class, et al.. (2022). Setup of human liver-chips integrating 3D models, microwells and a standardized microfluidic platform as proof-of-concept study to support drug evaluation. SHILAP Revista de lepidopterología. 7. 100054–100054. 17 indexed citations
4.
Walles, Markus, Michael J. Berna, Wenying Jian, et al.. (2022). A Cross Company Perspective on the Assessment of Therapeutic Protein Biotransformation. Drug Metabolism and Disposition. 50(6). 846–857. 10 indexed citations
5.
Jackson, Klarissa D., Upendra A. Argikar, Sungjoon Cho, et al.. (2022). Bioactivation and reactivity research advances – 2021 year in review. Drug Metabolism Reviews. 54(3). 246–281.
6.
Khojasteh, S. Cyrus, Upendra A. Argikar, James P. Driscoll, et al.. (2021). Novel advances in biotransformation and bioactivation research – 2020 year in review. Drug Metabolism Reviews. 53(3). 384–433. 6 indexed citations
7.
King, Lloyd, et al.. (2020). Evaluation of In Vitro Models for Assessment of Human Intestinal Metabolism in Drug Discovery. Drug Metabolism and Disposition. 48(11). 1169–1182. 22 indexed citations
8.
9.
Porter, John, Simon Lumb, Richard J. Franklin, et al.. (2009). Discovery of 4-azaindoles as novel inhibitors of c-Met kinase. Bioorganic & Medicinal Chemistry Letters. 19(10). 2780–2784. 33 indexed citations
10.
King, Lloyd, et al.. (2009). The PEG Moiety of Certolizumab Pegol is Rapidly Cleared From the Blood of Humans by the Kidneys Once it is Cleaved From the Fabʼ. Inflammatory Bowel Diseases. 15. S56–S56. 8 indexed citations
11.
King, Lloyd, et al.. (2009). The PEG Moiety of Certolizumab Pegol is Rapidly Cleared from the Blood of Humans by the Kidneys Once it is Cleaved from the Fabʼ. The American Journal of Gastroenterology. 104. S442–S443. 1 indexed citations
12.
King, Lloyd, et al.. (2008). Investigation of the Distribution and Elimination of the PEG Component of Certolizumab Pegol in Rats. The American Journal of Gastroenterology. 103. S431–S432. 1 indexed citations
13.
14.
Humphreys, David P., et al.. (2004). Engineering of Escherichia coli to improve the purification of periplasmic Fab′ fragments: changing the pI of the chromosomally encoded PhoS/PstS protein. Protein Expression and Purification. 37(1). 109–118. 9 indexed citations
15.
Humphreys, David P., Bruce Carrington, Bryan John Smith, et al.. (2002). A plasmid system for optimization of Fab′ production in Escherichia coli: importance of balance of heavy chain and light chain synthesis. Protein Expression and Purification. 26(2). 309–320. 39 indexed citations
16.
Humphreys, David P., Andrew P. Chapman, Bryan John Smith, et al.. (2000). High-Level Periplasmic Expression in Escherichia coli Using a Eukaryotic Signal Peptide: Importance of Codon Usage at the 5′ End of the Coding Sequence. Protein Expression and Purification. 20(2). 252–264. 55 indexed citations
17.
Humphreys, David P., Lloyd King, Shauna West, et al.. (2000). Improved efficiency of site-specific copper(II) ion-catalysed protein cleavage effected by mutagenesis of cleavage site. Protein Engineering Design and Selection. 13(3). 201–206. 19 indexed citations
18.
Humphreys, David P., et al.. (1999). Efficient site specific removal of a C-terminal FLAG fusion from a Fab′ using copper(II) ion catalysed protein cleavage. Protein Engineering Design and Selection. 12(2). 179–184. 21 indexed citations
19.
Humphreys, David P., Andrew P. Chapman, David J. King, et al.. (1998). F(ab′)2 molecules made from Escherichia coli produced Fab′ with hinge sequences conferring increased serum survival in an animal model. Journal of Immunological Methods. 217(1-2). 1–10. 24 indexed citations
20.
Boyd, Gary W., Helmut H. Zepik, Lloyd King, Costas Ioannides, & Maurice M. Coombs. (1993). SHORT COMMUNICATION: The in vitro metabolic activation of the 11-trifluoromethyl analogue of the potent carcinogen 15, 16-dihydro-11-methyl-cyclopenta[a]-phenanthren-17-one to mutagens. Carcinogenesis. 14(8). 1697–1699. 4 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Vladas Algirdas Bumelis Breakdown of academic impact, for papers by Mary Szatkowski Ozers Breakdown of academic impact, for papers by Christopher Chidley Breakdown of academic impact, for papers by Alexander S. McColl Breakdown of academic impact, for papers by Frédéric Villard Breakdown of academic impact, for papers by Bibek Parajuli Breakdown of academic impact, for papers by Anna C. Salzberg Breakdown of academic impact, for papers by Regina Tugyi Breakdown of academic impact, for papers by Mark E. Gustafson Breakdown of academic impact, for papers by Wanessa Fernanda Altei
Rankless by CCL
2026